Readings Newsletter
Become a Readings Member to make your shopping experience even easier.
Sign in or sign up for free!
You’re not far away from qualifying for FREE standard shipping within Australia
You’ve qualified for FREE standard shipping within Australia
The cart is loading…
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
This book highlights the role of nanotechnology concepts in the management of COVID-19 pandemic. The book covers different aspects of the causative agent SARS CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2) and the COVID-19 pandemic with a special emphasis on nanotechnology. It discusses the origin and history of SARS CoV2 and the outbreak of COVID-19 and highlights the geographical mutations in the SARS CoV2 virus genome, providing information about the structural features, antigenicity and the life cycle of SARS CoV2. The book provides an insight into nanotechnology-virology interface and explains how nanomaterials link the gap between the vital phases of SARS CoV2 life cycle and the four modalities of COVID-19 management viz sensing/diagnosis, therapy, prevention and self-protection. Further, the existing and promising diagnostic tools for detection of COVID-19 are discussed with an emphasis on nano PCR, nanoimmunosensors, biobarcode assay and point of care approach and also describe the nanoparticles involved in the CT imaging of lungs and SFHI (Spatial Frequency Hetrodyne Imaging) for diagnosis of SARS COV2 infection. The book concludes with details about translational medicine and explains the types of SARS CoV2 vaccines, stages of COVID-19 vaccine development and possible nanovaccines for COVID-19, followed by the description on biopharmaceutical companies involved in the production of SARS CoV2 vaccines.
$9.00 standard shipping within Australia
FREE standard shipping within Australia for orders over $100.00
Express & International shipping calculated at checkout
This title is printed to order. This book may have been self-published. If so, we cannot guarantee the quality of the content. In the main most books will have gone through the editing process however some may not. We therefore suggest that you be aware of this before ordering this book. If in doubt check either the author or publisher’s details as we are unable to accept any returns unless they are faulty. Please contact us if you have any questions.
This book highlights the role of nanotechnology concepts in the management of COVID-19 pandemic. The book covers different aspects of the causative agent SARS CoV2 (Severe Acute Respiratory Syndrome Coronavirus-2) and the COVID-19 pandemic with a special emphasis on nanotechnology. It discusses the origin and history of SARS CoV2 and the outbreak of COVID-19 and highlights the geographical mutations in the SARS CoV2 virus genome, providing information about the structural features, antigenicity and the life cycle of SARS CoV2. The book provides an insight into nanotechnology-virology interface and explains how nanomaterials link the gap between the vital phases of SARS CoV2 life cycle and the four modalities of COVID-19 management viz sensing/diagnosis, therapy, prevention and self-protection. Further, the existing and promising diagnostic tools for detection of COVID-19 are discussed with an emphasis on nano PCR, nanoimmunosensors, biobarcode assay and point of care approach and also describe the nanoparticles involved in the CT imaging of lungs and SFHI (Spatial Frequency Hetrodyne Imaging) for diagnosis of SARS COV2 infection. The book concludes with details about translational medicine and explains the types of SARS CoV2 vaccines, stages of COVID-19 vaccine development and possible nanovaccines for COVID-19, followed by the description on biopharmaceutical companies involved in the production of SARS CoV2 vaccines.